Schuiling M, Zuidhof A B, Zaagsma J, Meurs H
Department of Molecular Pharmacology, University Centre for Pharmacy, Groningen, The Netherlands.
Am J Respir Crit Care Med. 1999 Feb;159(2):423-30. doi: 10.1164/ajrccm.159.2.9804125.
It has been suggested that tachykinin NK1 receptor-mediated neurogenic inflammation, characterized by microvascular leakage, mucus secretion, and infiltration and activation of inflammatory cells in the airways, may be involved in allergic asthma. Therefore, in a guinea pig model of allergic asthma, we investigated the involvement of the NK1 receptor in allergen-induced early (EAR) and late (LAR) asthmatic reactions, airway hyperreactivity (AHR) after these reactions and airway inflammation, using the selective nonpeptide NK1 receptor antagonist SR140333. On two different occasions, separated by 1 wk interval, OA-sensitized guinea pigs inhaled either saline (3 min) or SR140333 (100 nM, 3 min) at 30 min before as well as at 5.5 h after OA provocation (between the EAR and LAR) in a random crossover design. A control group, receiving saline inhalations before and at 5.5 h after the two OA provocations, was included as well. SR140333 had no significant effect on either the EAR or the LAR compared with saline control inhalations. However, the NK1 receptor antagonist significantly reduced the OA-induced AHR to histamine, both after the EAR at 5 h after OA challenge (1.77 +/- 0.13-fold increase in histamine reactivity versus 2.50 +/- 0.25-fold increase in the control animals, p < 0.01) and after the LAR at 23 h after OA challenge (1.15 +/- 0.12-fold increase versus 1.98 +/- 0. 34-fold increase, respectively, p < 0.05). Moreover, bronchoalveolar lavage studies performed at 25 h after the second OA provocation indicated that SR140333 significantly inhibited the allergen-induced infiltration of eosinophils, neutrophils, and lymphocytes in the airways (p < 0.05 for all observations), whereas a tendency to reduced accumulation of ciliated epithelial cells in the airway lumen was observed (p = 0.10). These results indicate that the NK1 receptor is involved in the development of allergen-induced AHR to histamine, and that NK1 receptor-mediated infiltration of inflammatory cells in the airways may contribute to this AHR.
有人提出,速激肽NK1受体介导的神经源性炎症,其特征为气道中的微血管渗漏、黏液分泌以及炎性细胞的浸润和活化,可能与过敏性哮喘有关。因此,在过敏性哮喘豚鼠模型中,我们使用选择性非肽类NK1受体拮抗剂SR140333,研究了NK1受体在变应原诱导的早期(EAR)和晚期(LAR)哮喘反应、这些反应后的气道高反应性(AHR)以及气道炎症中的作用。在两个不同的时间点,间隔1周,对卵清蛋白致敏的豚鼠采用随机交叉设计,在卵清蛋白激发前30分钟以及激发后5.5小时(在EAR和LAR之间)吸入生理盐水(3分钟)或SR140333(100 nM,3分钟)。还包括一个对照组,在两次卵清蛋白激发前和激发后5.5小时吸入生理盐水。与生理盐水对照吸入相比,SR140333对EAR或LAR均无显著影响。然而,NK1受体拮抗剂显著降低了卵清蛋白诱导的对组胺的AHR,在卵清蛋白激发后5小时的EAR后(组胺反应性增加1.77±0.13倍,而对照动物增加2.50±0.25倍,p<0.01)以及卵清蛋白激发后23小时的LAR后(分别增加1.15±0.12倍和1.98±0.34倍,p<0.05)。此外,在第二次卵清蛋白激发后25小时进行的支气管肺泡灌洗研究表明,SR140333显著抑制了变应原诱导的气道中嗜酸性粒细胞、中性粒细胞和淋巴细胞的浸润(所有观察结果p<0.05),而观察到气道腔内纤毛上皮细胞积累有减少的趋势(p = 0.10)。这些结果表明,NK1受体参与了变应原诱导的对组胺的AHR的发展,并且NK1受体介导的气道炎性细胞浸润可能促成了这种AHR。